Radiogenomics: Lung Cancer-Related Genes Mutation Status Prediction
- 1 Citations
- 562 Downloads
Abstract
Advances in genomics have driven to the recognition that tumours are populated by different minor subclones of malignant cells that control the way the tumour progresses. However, the spatial and temporal genomic heterogeneity of tumours has been a hurdle in clinical oncology. This is mainly because the standard methodology for genomic analysis is the biopsy, that besides being an invasive technique, it does not capture the entire tumour spatial state in a single exam. Radiographic medical imaging opens new opportunities for genomic analysis by providing full state visualisation of a tumour at a macroscopic level, in a non-invasive way. Having in mind that mutational testing of EGFR and KRAS is a routine in lung cancer treatment, it was studied whether clinical and imaging data are valuable for predicting EGFR and KRAS mutations in a cohort of NSCLC patients. A reliable predictive model was found for EGFR (AUC = 0.96) using both a Multi-layer Perceptron model and a Random Forest model but not for KRAS (AUC = 0.56). A feature importance analysis using Random Forest reported that the presence of emphysema and lung parenchymal features have the highest correlation with EGFR mutation status. This study opens new opportunities for radiogenomics on predicting molecular properties in a more readily available and non-invasive way.
Keywords
Radiogenomics Mutation status Predictive modelsNotes
Acknowledgments
This work is financed by the ERDF – European Regional Development Fund through the Operational Programme for Competitiveness and Internationalisation - COMPETE 2020 Programme and by National Funds through the Portuguese funding agency, FCT - Fundação para a Ciência e a Tecnologia within project POCI-01-0145-FEDER-030263.
References
- 1.Bakr, S., et al.: A radiogenomic dataset of non-small cell lung cancer. Sci. Data 5, 180202 (2018)CrossRefGoogle Scholar
- 2.Bakr, S., et al.: Data for NSCLC Radiogenomics Collection (2017). https://doi.org/10.7937/K9/TCIA.2017.7hs46erv. https://wiki.cancerimagingarchive.net/x/W4G1AQ, type: dataset
- 3.Breiman, L.: Random forests. Mach. Learn. 45(1), 5–32 (2001)CrossRefGoogle Scholar
- 4.Chawla, N.V., Bowyer, K.W., Hall, L.O., Kegelmeyer, W.P.: Smote: synthetic minority over-sampling technique. J. Artif. Intell. Res. 16, 321–357 (2002)CrossRefGoogle Scholar
- 5.Chen, Z., Fillmore, C.M., Hammerman, P.S., Kim, C.F., Wong, K.K.: Non-small-cell lung cancers: a heterogeneous set of diseases. Nat. Rev. Cancer 14(8), 535 (2014)CrossRefGoogle Scholar
- 6.Clark, K., et al.: The cancer imaging archive (TCIA): maintaining and operating a public information repository. J. Digit. Imaging 26(6), 1045–1057 (2013). https://doi.org/10.1007/s10278-013-9622-7CrossRefGoogle Scholar
- 7.Digumarthy, S.R., Padole, A.M., Gullo, R.L., Sequist, L.V., Kalra, M.K.: Can CT radiomic analysis in NSCLC predict histology and EGFR mutation status? Medicine 98(1) (2019)CrossRefGoogle Scholar
- 8.Dogan, S., et al.: Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers. Clin. Cancer Res. 18(22), 6169–6177 (2012)CrossRefGoogle Scholar
- 9.Ellison, G., Zhu, G., Moulis, A., Dearden, S., Speake, G., McCormack, R.: EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J. Clin. Pathol. 66(2), 79–89 (2013)CrossRefGoogle Scholar
- 10.Ferlay, J., et al.: Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int. J. Cancer 136(5), E359–E386 (2015)CrossRefGoogle Scholar
- 11.Gevaert, O., et al.: Predictive radiogenomics modeling of EGFR mutation status in lung cancer. Sci. Rep. 7, 41674 (2017)CrossRefGoogle Scholar
- 12.Gevaert, O., et al.: Non–small cell lung cancer: identifying prognostic imaging biomarkers by leveraging public gene expression microarray data—methods and preliminary results. Radiology 264(2), 387–396 (2012). https://doi.org/10.1148/radiol.12111607, pMID: 22723499CrossRefGoogle Scholar
- 13.Hames, M.L., Chen, H., Iams, W., Aston, J., Lovly, C.M., Horn, L.: Correlation between KRAS mutation status and response to chemotherapy in patients with advanced non-small cell lung cancer. Lung Cancer 92, 29–34 (2016)CrossRefGoogle Scholar
- 14.Hansell, D.M., Bankier, A.A., MacMahon, H., McLoud, T.C., Muller, N.L., Remy, J.: Fleischner society: glossary of terms for thoracic imaging. Radiology 246(3), 697–722 (2008)CrossRefGoogle Scholar
- 15.Janssen-Heijnen, M.L., Coebergh, J.W.W.: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31(2–3), 123–137 (2001)CrossRefGoogle Scholar
- 16.Liu, Y., et al.: Radiomic features are associated with EGFR mutation status in lung adenocarcinomas. Clin. Lung Cancer 17(5), 441–448 (2016)CrossRefGoogle Scholar
- 17.Mei, D., Luo, Y., Wang, Y., Gong, J.: CT texture analysis of lung adenocarcinoma: can radiomic features be surrogate biomarkers for EGFR mutation statuses. Cancer Imaging 18(1), 52 (2018)CrossRefGoogle Scholar
- 18.Mok, T.S., et al.: Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N. Engl. J. Med. 361(10), 947–957 (2009)CrossRefGoogle Scholar
- 19.O’dowd, E.L., et al.: What characteristics of primary care and patients are associated with early death in patients with lung cancer in the UK? Thorax 70(2), 161–168 (2015)CrossRefGoogle Scholar
- 20.Papadopoulou, E., et al.: Determination of EGFR and KRAS mutational status in greek non-small-cell lung cancer patients. Oncol. Lett. 10(4), 2176–2184 (2015)CrossRefGoogle Scholar
- 21.Riely, G.J., Marks, J., Pao, W.: KRAS mutations in non–small cell lung cancer. Proc. Am. Thorac. Soc. 6(2), 201–205 (2009)CrossRefGoogle Scholar
- 22.Rosenblatt, F.: The perceptron: a probabilistic model for information storage and organization in the brain. Psychol. Rev. 65(6) (1958)CrossRefGoogle Scholar
- 23.Scrivener, M., de Jong, E.E., van Timmeren, J.E., Pieters, T., Ghaye, B., Geets, X.: Radiomics applied to lung cancer: a review. Transl. Cancer Res. 5(4), 398–409 (2016)CrossRefGoogle Scholar
- 24.Siegelin, M.D., Borczuk, A.C.: Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab. Invest. 94(2), 129 (2014)CrossRefGoogle Scholar
- 25.Varghese, A.M., et al.: Lungs dont forget: comparison of the KRAS and EGFR mutation profile and survival of collegiate smokers and never smokers with advanced lung cancers. J. Thorac. Oncol. 8(1), 123–125 (2013)CrossRefGoogle Scholar
- 26.Zhou, H., et al.: Poor response to platinum-based chemotherapy is associated with KRAS mutation and concomitant low expression of BRAC1 and TYMS in NSCLC. J. Int. Med. Res. 44(1), 89–98 (2016)CrossRefGoogle Scholar